Skip to main content
TipRanks
Go Ultimate75% OFF

Sonic Healthcare (SKHHY) AI Stock Analysis

20 Followers
SKHHY

Sonic Healthcare

(Other OTC:SKHHY)

Select Model
Rating:64Neutral
Price Target:$14.00â–²(3.85% Upside)
Action:reiterated
Date:08/22/26

Overall score is driven primarily by solid but not standout financial performance (strong growth, moderated margins/returns, and weaker cash conversion) and a constructive earnings-call backdrop tempered by meaningful near-term headwinds and conservative guidance. Valuation helps notably thanks to a strong dividend yield and reasonable P/E, while technical indicators are mixed with modest momentum but some near-term softness.

Positive Factors
Strong Revenue and Profit GrowthBroad-based revenue, EBITDA and profit growth indicates that Sonic is expanding its diagnostic platform while converting demand into earnings. Continued scale across pathology and imaging can support reinvestment, strengthen customer reach, and provide a durable base for growth over the next several quarters.
Negative Factors
Swiss Regulatory Fee ReductionThe Swiss fee change is a structural reimbursement headwind rather than a temporary fluctuation, directly reducing revenue and putting pressure on margins. Sonic may offset part of the impact through synergies, but the regulatory reset lowers earnings quality and limits near-term growth in that market.

Sonic Healthcare (SKHHY) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%SKHHY+4.39%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.66B
Dividend Yield
5.70%
Average Volume (3M)
114.09K
Price to Earnings (P/E)
16.1
Beta (1Y)
0.41
Revenue Growth
19.96%
EPS Growth
21.43%
Country
US
Employees
49,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Sonic Healthcare Business Overview & Revenue Model

Company Description

Headquartered in Sydney, Australia, Sonic Healthcare Limited, established in 1934, is a global provider of medical diagnostic and healthcare services. The company delivers a comprehensive range of laboratory medicine (pathology) services, alongside e...

How the Company Makes Money

Sonic Healthcare primarily makes money by delivering diagnostic services and receiving payment for each service performed. Its two main revenue streams are: (1) Pathology/Laboratory services: revenue is generated from clinical laboratory tests such a...

Sonic Healthcare Earnings Call Summary

Earnings Call Date:Aug 19, 2026(Q4-2026)|% Change Since:-17.15%|Next Earnings Date:Feb 22, 2027
Earnings Call SentimentPositive

The call conveyed a predominantly positive performance picture: strong revenue, EBITDA and NPAT growth, solid organic expansion, and notable success in advanced diagnostics and M&A integration (notably Germany and Switzerland). Management also outlined proactive investments in digital transformation and clear U.S. turnaround actions expected to deliver AUD 25–30 million in FY2027 earnings. However, several near-term headwinds were emphasized, including regulatory fee cuts in Switzerland (CHF 20m), U.K. contract integration delays, software impairments and legacy IT write-downs, higher interest and capex in FY2026, FX and policy uncertainties (PAMA, GOÄ). On balance the highlights (growth, synergy capture, digital investment and disciplined capital management) outweigh the lowlights, although they limit near-term upside and keep guidance conservative.

Positive Updates

Strong Top-Line and Profit Growth
Total revenue grew 13% year-on-year to AUD 10.867 billion; underlying EBITDA increased 11% to AUD 1.933 billion (AUD 1.916 billion constant currency); net profit after tax rose 17% to AUD 621 million and EPS increased 14% to AUD 1.26.

Negative Updates

Regulatory Fee Headwinds in Switzerland
Regulatory changes effective 1 July 2026 are expected to reduce FY2027 revenue in Switzerland by an estimated CHF 20 million (approximately 3% of Swiss revenue) and will directly pressure top-line and margins unless fully mitigated by synergies.

Company Guidance

Guidance for FY2027 is for constant‑currency EBITDA of AUD 1.95–2.03 billion (note this excludes ~AUD 30 million of back‑office IT transformation costs), with depreciation forecast at AUD 810–825 million, amortisation AUD 90–95 million, interest expense expected to rise ~6% versus FY2026 and an effective tax rate of ~27%; the guidance assumes only completed acquisitions, no future regulatory changes (PAMA fee cuts excluded), current interest rates and excludes any property sale gains. Management expects the U.S. operating review to contribute c. AUD 25–30 million to FY2027 earnings, while a Swiss regulatory fee change is estimated to reduce FY2027 revenue by CHF 20 million (≈3% of Swiss revenue); foreign‑exchange movements at current spot rates could imply a c. AUD 40–50 million headwind to group EBITDA. Capital discipline remains a priority: maintenance CapEx is around 3% of revenue (FY2026 maintenance CapEx ~AUD 351 million), property‑related CapEx is expected to fall from FY2028 levels, the medium‑term dividend payout target is 70–80% of net profit (FY2026 full‑year dividend AUD 1.08, final AUD 0.63, 60% franked), and balance‑sheet metrics include a FY2026 net debt cover ratio of 2.2 and available headroom of ~AUD 1.6 billion pre‑dividend.

Sonic Healthcare Financial Statement Overview

Summary

Income statement shows strong recent revenue momentum but only mid-single-digit margins and profitability well below prior peak years. Balance sheet is supported by substantial equity, though leverage has risen (debt-to-equity trending up) and ROE has cooled. Cash flow remains positive, but cash conversion has weakened (operating cash flow and free cash flow running below net income in recent years), adding inconsistency risk.

Income Statement

64Positive

Balance Sheet

62Positive

Cash Flow

57Neutral
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue10.93B10.71B9.65B8.93B7.96B9.31B
Gross Profit3.03B2.96B3.19B2.94B2.11B3.41B
EBITDA1.95B1.91B1.75B1.63B1.72B2.80B
Net Income608.36M595.00M513.60M511.09M684.98M1.46B
Balance Sheet
Total Assets16.78B16.78B16.05B14.83B13.56B13.11B
Cash, Cash Equivalents and Short-Term Investments653.73M653.73M673.77M645.00M797.99M780.00M
Total Debt5.84B5.84B5.17B4.52B3.10B3.01B
Total Liabilities8.29B8.29B7.58B6.75B5.64B5.68B
Stockholders Equity8.34B8.34B8.32B7.92B7.74B7.27B
Cash Flow
Free Cash Flow798.37M757.78M960.55M492.01M974.02M1.85B
Operating Cash Flow1.45B1.37B1.30B1.07B1.47B2.23B
Investing Cash Flow-944.23M-877.39M-577.62M-1.81B-580.04M-989.18M
Financing Cash Flow-512.69M-500.78M-735.93M592.41M-911.51M-1.35B

Sonic Healthcare Technical Analysis

Technical Analysis SentimentNegative
Last Price13.48

Price Trends

50DMA13.41Positive
100DMA14.01Negative
200DMA14.02Negative

Market Momentum

MACD0.08Negative
RSI49.81Neutral
STOCH1.32Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SKHHY, the sentiment is Negative. The current price of 13.48 is below the 20-day moving average (MA) of 13.48, above the 50-day MA of 13.41, and below the 200-day MA of 14.02, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 49.81 is Neutral, neither overbought nor oversold. The STOCH value of 1.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SKHHY.

Sonic Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SKHHY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DGXDGX76Outperform$28.56B25.5015.21%1.30%9.13%17.93%
LHLH75Outperform$30.08B30.1911.54%0.78%6.02%19.63%
NEONEO68Neutral$2.07B-64.91-3.97%―11.08%71.76%
SKHHYSKHHY64Neutral$6.65B16.147.20%5.70%19.96%21.43%
RDNTRDNT55Neutral$6.02B-265.53-2.04%―21.06%-70.26%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GHGH44Neutral$20.52B-41.22249.03%―41.69%-14.59%

* Healthcare Sector Average

Performance Comparison

0%50%SKHHYLHDGXRDNTNEOGHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SKHHY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SKHHYSonic Healthcare Limited13.480.453.45%
LHLabcorp Holdings Inc.370.48111.7343.18%
DGXQuest Diagnostics259.6076.4941.77%
RDNTRadnet76.42-0.62-0.80%
NEONeoGenomics Inc.16.025.8056.75%
GHGuardant Health151.7055.2257.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 22, 2026